JAKAVI (ruxolitinib), protein kinase inhibitor

ONCOLOGY - Update

Opinions on drugs - Posted on May 10 2017

Nouvel examen suite au dépôt de nouvelles données

Since 2012, JAKAVI has had marketing authorisation in the treatment of splenomegaly or symptoms related to primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis.
Its efficacy has been established based on reduction in spleen volume and on the resulting symptoms.
The new data do not change the previous assessment: JAKAVI provides moderate clinical added value in its indication.

Substantial

moderate

Therapeutic use

Évaluation des médicaments

My account